- Home
- MYN vs RIGL Comparison
MYN vs RIGL Comparison
Compare MYN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYN
- RIGL
- Stock Information
- Founded
- MYN 1992
- RIGL 1996
- Country
- MYN United States
- RIGL United States
- Employees
- MYN N/A
- RIGL N/A
- Industry
- MYN Finance Companies
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- MYN Finance
- RIGL Health Care
- Exchange
- MYN Nasdaq
- RIGL Nasdaq
- Market Cap
- MYN 411.5M
- RIGL 486.4M
- IPO Year
- MYN N/A
- RIGL 2000
- Fundamental
- Price
- MYN $10.06
- RIGL $17.09
- Analyst Decision
- MYN
- RIGL Buy
- Analyst Count
- MYN 0
- RIGL 5
- Target Price
- MYN N/A
- RIGL $34.80
- AVG Volume (30 Days)
- MYN 86.0K
- RIGL 203.8K
- Earning Date
- MYN 01-01-0001
- RIGL 11-07-2024
- Dividend Yield
- MYN 4.12%
- RIGL N/A
- EPS Growth
- MYN N/A
- RIGL N/A
- EPS
- MYN N/A
- RIGL 0.22
- Revenue
- MYN N/A
- RIGL $157,374,000.00
- Revenue This Year
- MYN N/A
- RIGL $48.98
- Revenue Next Year
- MYN N/A
- RIGL $14.43
- P/E Ratio
- MYN N/A
- RIGL $77.18
- Revenue Growth
- MYN N/A
- RIGL 21.65
- 52 Week Low
- MYN $8.47
- RIGL $7.48
- 52 Week High
- MYN $10.62
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- MYN 27.74
- RIGL 30.82
- Support Level
- MYN $10.59
- RIGL $16.68
- Resistance Level
- MYN $10.71
- RIGL $19.80
- Average True Range (ATR)
- MYN 0.09
- RIGL 1.53
- MACD
- MYN -0.06
- RIGL -1.05
- Stochastic Oscillator
- MYN 1.52
- RIGL 3.66
About MYN Blackrock MuniYield New York Quality Fund Inc.Common Stock
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests primarily in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.